Krause Kevin's Insider Trades & SAST Disclosures
Krause Kevin's most recent trade in AN2 Therapeutics Inc was a trade of 60,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 15, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Krause Kevin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 30,000 | 31,914 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 15 Mar 2024 | 30,000 | 31,914 | - | 0 | Common Stock | ||
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 09 Jan 2024 | 7,417 | 1,914 | - | 20.1 | 149,367 | Common Stock | |
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 09 Jan 2024 | 5,000 | 9,331 | - | 6.6 | 33,000 | Common Stock | |
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 09 Jan 2024 | 5,000 | 26,832 | - | - | Stock Option (right to buy) | ||
| AN2 Therapeutics Inc | Krause Kevin | Chief Strategy Officer | 09 Jan 2024 | 2,417 | 49,868 | - | - | Stock Option (right to buy) | ||
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 09 Jan 2024 | 2,417 | 4,331 | - | 0.4 | 1,015 | Common Stock | |
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 02 Jan 2024 | 2,583 | 4,497 | - | 0.4 | 1,085 | Common Stock | |
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 02 Jan 2024 | 2,583 | 1,914 | - | 20.1 | 51,967 | Common Stock | |
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 02 Jan 2024 | 2,583 | 52,285 | - | - | Stock Option (right to buy) | ||
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 15 Feb 2023 | 62,200 | 62,200 | - | - | Stock Option (right to buy) | ||
| AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 12 May 2022 | 66,000 | 66,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges